3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Phase 2
1
Status
Recruiting
4
Completed
4
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
4
Sponsor
Cancer Type
Breast
4
Sarcoma
1
Gynecologic
1
CNS
1
Conditions
Breast Neoplasms
3
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
78
Fulvestrant
76
Carboplatin
74
Trastuzumab
71
Capecitabine
69
Letrozole
62
Cyclophosphamide
61
Paclitaxel
60
pertuzumab
52
Specimen Handling
52
Docetaxel
50
abemaciclib
46
ribociclib
44
Anastrozole
35
130-nm albumin-bound paclitaxel
35
trastuzumab deruxtecan
34
Magnetic Resonance Spectroscopy
33
Blood Specimen Collection
33
Tamoxifen
32
sacituzumab govitecan
31
exemestane
31
Biopsy
31
Gemcitabine
30
Epirubicin
29
pyrotinib
28
palbociclib
28
Surveys and Questionnaires
27
Injections
27
Drug Therapy
27
eribulin
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Recruiting
×
RAD1901
×
Breast
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled
NCT07198724
2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2
Recruiting
65 enrolled
NCT06382948
2026-04-03
ADELA
MedSIR
Phase 3
Recruiting
240 enrolled
NCT07222215
2026-01-22
CAPELA
Dana-Farber Cancer Institute
Phase 2
Recruiting
297 enrolled